siRNA-based therapy ameliorates glomerulonephritis - Wikidata - awgldk - TriplyDB

siRNA-based therapy ameliorates glomerulonephritis

siRNA-based therapy ameliorates glomerulonephritis

http://www.wikidata.org/entity/Q33748522

about

Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect Fighting against kidney diseases with small interfering RNA: opportunities and challenges Kidney-specific Sonoporation-mediated Gene Transfer.Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice.Mesangial pathology in glomerular disease: targets for therapeutic intervention.Applications of proteomic technologies for understanding the premature proteolysis of CFTR.siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA Impairment of hepatic nuclear factor-4α binding to the Stim1 promoter contributes to high glucose-induced upregulation of STIM1 expression in glomerular mesangial cells Store-Operated Ca2+ Channels in Mesangial Cells Inhibit Matrix Protein Expression.Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides New short interfering RNA-based therapies for glomerulonephritis.MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring.siRNA technology in kidney transplantation: current status and future potential.Transcription factors and epigenetic modulation: its therapeutic implication in chronic kidney disease.Nanomedicines for kidney diseases.Single siRNA nanocapsules for enhanced RNAi delivery Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis siRNAs targeted to Smad4 prevent renal fibrosis in vivo.In Vivo siRNA Delivery and Rebound of Renal LRP2 in Mice.Modulating the immune system through nanotechnology.Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice.

P2860

Q24295031-E7979470-BB4B-4DC2-A0E8-411E08E64408 Q27010574-7A180473-4A04-4846-8306-CA8D64CADD85 Q30389264-B72C9074-B35B-40D7-874C-AC75978184FE Q30427986-9911E1BB-5C54-40D1-9759-130DEC429B6B Q30429535-7CAEF823-E5B3-42BE-833D-485F2CA97B0D Q34076025-197CBD0B-22F3-422E-B2A1-6BA014E769BB Q35224125-8B5F4825-85D0-4966-8E8F-AFA6766FBA49 Q35622475-92909657-2971-41CF-AE4D-A6E6385A2CBF Q36223317-5F8815F6-131C-475F-B954-712DC675187B Q37015817-AAAE2424-87F9-4470-9037-ACCF25C2DA1A Q37879444-569DDBF9-4493-45EC-B84D-BB889F9E4437 Q38115932-D3B5E11D-A157-431B-9CD5-2A2D1AB183EA Q38191482-2E040F74-5877-4F4B-A428-1530D74DD6B7 Q38287288-2BCBBCE4-2F8F-48E5-B25C-DE49F79BAD85 Q38862723-31284E81-9069-4C97-B533-5903574C28A1 Q39301867-6029ABD4-9E8D-4B5D-867E-27983EE0BCB0 Q41896485-CE35A711-EEE6-4252-B94E-0206DC7DD7C3 Q42376017-009F4396-2E7B-4D9A-A667-DE7566E06A26 Q42905735-9BB199AE-FB54-427E-9744-A057F3D78883 Q48093995-B3027F7A-18C1-4DF4-A087-1073FD9D3412 Q48630939-AF3F3288-EC80-41C7-9495-D333E81E7605 Q50877858-79F3BC21-D663-4F91-AC03-15017A287294

P2860

siRNA-based therapy ameliorates glomerulonephritis

http://www.wikidata.org/entity/Q33748522

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

siRNA-based therapy ameliorates glomerulonephritis

@ast

siRNA-based therapy ameliorates glomerulonephritis

@en

type

label

siRNA-based therapy ameliorates glomerulonephritis

@ast

siRNA-based therapy ameliorates glomerulonephritis

@en

prefLabel

siRNA-based therapy ameliorates glomerulonephritis

@ast

siRNA-based therapy ameliorates glomerulonephritis

@en

P1433

Q33748522-F5AB1F98-A2A3-4F80-8641-30BC252B97D5

P1476

Q33748522-8058408F-BAFA-4DD2-AC7D-E35CFC88AD3A

P2093

Q33748522-05140E5C-5354-4FA3-832C-44C457A21A0A

Q33748522-1D5B34BC-DD8D-4E68-AB33-F7C1A6C96DCD

Q33748522-2FDC2601-8D03-451D-8024-7DEA953E8146

Q33748522-3CFA2BD3-A1CC-4DC8-8A07-880905342F16

Q33748522-45A8E449-B92E-4F41-BA47-19A8EC5AE122

Q33748522-5633667A-CD17-44C3-8299-016F800EA945

Q33748522-56B328E5-01ED-40AB-B82B-1AA6DBE9E329

Q33748522-5F3B5A59-14A0-4C6F-AED9-D834172CAE51

Q33748522-7953EACF-B025-48E2-82E1-EA7044756B36

Q33748522-A6E0829C-BAB3-4068-AEE3-F9F0C78BB6F8

P2860

Q33748522-0A24BCFC-128F-4381-A70D-5A1AA10947D5

Q33748522-0DC15C0A-BF5F-4638-AA36-8596CFF3AC6C

Q33748522-0E208E66-0BB9-4F70-AE5C-6E83D7727A66

Q33748522-113B0738-081D-4467-AE89-48AFC7549D23

Q33748522-11635D42-1F3E-4468-80E4-D8C7A8CB122C

Q33748522-11AA7C8A-31DB-4F0A-869F-0FF134EBE197

Q33748522-131A3D13-46F8-4999-B861-1DABC2C2F12D

Q33748522-19DD2BFB-6B66-4A93-BA10-F5E1E2CAFCC7

Q33748522-1D745A21-22EB-41FD-98FD-F6541FD50EF2

Q33748522-1ED3EFE8-9C02-41C0-B3ED-2AD2C662C6D2

P304

Q33748522-1DE178D4-ABF7-48FD-8018-BB1934A4DCFC

P31

Q33748522-2A2159AE-843B-4894-A9A0-EA4DCB6051F2

P356

Q33748522-D5F4CF7A-AE1C-4EBB-8F8C-7CEA4F55C3DC

P433

Q33748522-2101E74D-F424-4E87-A6F2-1EC5805E3006

P478

Q33748522-B030FADE-63C9-4484-B152-090B83DF074B

P577

Q33748522-4F597760-715C-44C2-AAED-A90881725F9F

P5875

Q33748522-ECED5DAA-301B-4482-942F-2EA1ECCC80DB

P698

Q33748522-6F7991DA-D419-4490-A4EC-67112E9F1DAD

P921

Q33748522-4552819A-196E-464F-93F0-3960079F327E

P932

Q33748522-134B0F55-A546-4FA2-AE90-A2A6794227A6

P356

P1433

Journal of the American Society of Nephrology

P1476

siRNA-based therapy ameliorates glomerulonephritis

@en

P2093

Akira Yamada

http://www.w3.org/2001/XMLSchema#string

Hideki Shimizu

http://www.w3.org/2001/XMLSchema#string

Kanjiro Miyata

http://www.w3.org/2001/XMLSchema#string

Kazunori Kataoka

http://www.w3.org/2001/XMLSchema#string

Koei Yamada

http://www.w3.org/2001/XMLSchema#string

Makoto Oba

http://www.w3.org/2001/XMLSchema#string

Nobuhiro Nishiyama

http://www.w3.org/2001/XMLSchema#string

Satoru Matsumoto

http://www.w3.org/2001/XMLSchema#string

Shinya Kaname

http://www.w3.org/2001/XMLSchema#string

Toshiro Fujita

http://www.w3.org/2001/XMLSchema#string

P2860

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

Strategies for silencing human disease using RNA interference

p38 MAPK signalling cascades in inflammatory disease

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation.

MAPK signaling and the kidney.

Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease.

Gene therapy in renal diseases.

On future's doorstep: RNA interference and the pharmacopeia of tomorrow.

Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains

P304

622-633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2009030295

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41760666

http://www.w3.org/2001/XMLSchema#string

P698

20203158

http://www.w3.org/2001/XMLSchema#string

P921

glomerulonephritis

P932

2844303

http://www.w3.org/2001/XMLSchema#string